Synbio Pharmaceuticals ＜4582＞ announced on the 8th that it has begun clinical trials targeting cytomegalovirus infection (CMV infection) after hematopoietic stem cell transplantation in a phase 2a clinical trial (ATHENA test) with the injectable brincidofovir.

The company plans to complete the injectable brincidofovir phase 2a clinical trial targeting adenovirus infection (AdV infection) after hematopoietic stem cell transplantation in the first half of the 2024/12 fiscal year.

This time, it is a clinical trial targeting CMV infection after hematopoietic stem cell transplantation, which is the second indication, and diligent preparations are underway with major transplantation facilities in the United States for the first patient administration. The test is part of the ATHENA exam, and it was decided that the test period for the ATHENA exam will be extended. In clinical trials of oral BCV, it has been recognized that BCV is highly effective against CMV infections, and clinical trials using highly safe injectable BCV will be carried out in the same trial.